Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caroline Trang-Poisson

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Trials|June 5, 2020
Impact of fecal microbiota transplantation on chronic recurrent pouchitis in ulcerative colitis with ileo-anal anastomosis: study protocol for a prospective, multicenter, double-blind, randomized, controlled trialCaroline Trang-Poisson, Elise Kerdreux, Alexandra Poinas, et al.
Alimentary Pharmacology & Therapeutics|June 6, 2019
Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort studyAurelien Amiot, Melanie Serrero, Laurent Peyrin-Biroulet, et al.
Alimentary Pharmacology & Therapeutics|April 5, 2021
Determinants of IBD-related disability: a cross-sectional survey from the GETAIDJenny Tannoury, Maria Nachury, Carole Martins, et al.
Journal of Crohn'S & Colitis|May 7, 2019
Vedolizumab Therapy is Ineffective for Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A GETAID Multicentre Cohort StudyBenedicte Caron, Laurent Peyrin-Biroulet, Benjamin Pariente, et al.
Inflammatory Bowel Diseases|June 2, 2017
Comparative Acceptability and Perceived Clinical Utility of Monitoring Tools: A Nationwide Survey of Patients with Inflammatory Bowel DiseaseAnthony Buisson, Florent Gonzalez, Florian Poullenot, et al.
Alimentary Pharmacology & Therapeutics|December 24, 2019
A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's diseaseParambir S Dulai, Aurelien Amiot, Laurent Peyrin-Biroulet, et al.
Frontiers in Immunology|September 13, 2023
The risk of COVID-19 in IBD patients is increased by urban living and is not influenced by disease activity or intravenous biologicsMargaux Lelong, Régis Josien, Marianne Coste-Burel, et al.
Inflammatory Bowel Diseases|October 12, 2021
Bariatric Surgery in Patients With Inflammatory Bowel Disease: A Case-Control Study from the GETAIDCatherine Reenaers, Arnaud de Roover, Laurent Kohnen, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 27, 2016
Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel DiseaseAurelien Amiot, Jean-Charles Grimaud, Laurent Peyrin-Biroulet, et al.
Journal of Crohn'S & Colitis|November 27, 2020
The IBD-disk Is a Reliable Tool to Assess the Daily-life Burden of Patients with Inflammatory Bowel DiseaseSara Tadbiri, Maria Nachury, Yoram Bouhnik, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Trials|June 5, 2020
Impact of fecal microbiota transplantation on chronic recurrent pouchitis in ulcerative colitis with ileo-anal anastomosis: study protocol for a prospective, multicenter, double-blind, randomized, controlled trialCaroline Trang-Poisson, Elise Kerdreux, Alexandra Poinas, et al.
Alimentary Pharmacology & Therapeutics|June 6, 2019
Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort studyAurelien Amiot, Melanie Serrero, Laurent Peyrin-Biroulet, et al.
Alimentary Pharmacology & Therapeutics|April 5, 2021
Determinants of IBD-related disability: a cross-sectional survey from the GETAIDJenny Tannoury, Maria Nachury, Carole Martins, et al.
Journal of Crohn'S & Colitis|May 7, 2019
Vedolizumab Therapy is Ineffective for Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A GETAID Multicentre Cohort StudyBenedicte Caron, Laurent Peyrin-Biroulet, Benjamin Pariente, et al.
Inflammatory Bowel Diseases|June 2, 2017
Comparative Acceptability and Perceived Clinical Utility of Monitoring Tools: A Nationwide Survey of Patients with Inflammatory Bowel DiseaseAnthony Buisson, Florent Gonzalez, Florian Poullenot, et al.
Alimentary Pharmacology & Therapeutics|December 24, 2019
A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's diseaseParambir S Dulai, Aurelien Amiot, Laurent Peyrin-Biroulet, et al.
Frontiers in Immunology|September 13, 2023
The risk of COVID-19 in IBD patients is increased by urban living and is not influenced by disease activity or intravenous biologicsMargaux Lelong, Régis Josien, Marianne Coste-Burel, et al.
Inflammatory Bowel Diseases|October 12, 2021
Bariatric Surgery in Patients With Inflammatory Bowel Disease: A Case-Control Study from the GETAIDCatherine Reenaers, Arnaud de Roover, Laurent Kohnen, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 27, 2016
Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel DiseaseAurelien Amiot, Jean-Charles Grimaud, Laurent Peyrin-Biroulet, et al.
Journal of Crohn'S & Colitis|November 27, 2020
The IBD-disk Is a Reliable Tool to Assess the Daily-life Burden of Patients with Inflammatory Bowel DiseaseSara Tadbiri, Maria Nachury, Yoram Bouhnik, et al.
Pageof 3